Molecular Cancer Therapeutics: 10 (1)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther January 1 2011 10 (1) 1-1;

Spotlight on Clinical Response

Spotlight on Clinical Response | Free Article

Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

Maria C. Villarroel, N.V. Rajeshkumar, Ignacio Garrido-Laguna, Ana De Jesus-Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison Klein, Daniel Laheru, Ross Donehower and Manuel Hidalgo

Mol Cancer Ther January 1 2011 10 (1) 3-8; DOI:10.1158/1535-7163.MCT-10-0893

Review

Review

Notch Signaling Pathway as a Therapeutic Target in Breast Cancer

Hamed Al-Hussaini, Deepa Subramanyam, Michael Reedijk and Srikala S. Sridhar

Mol Cancer Ther January 1 2011 10 (1) 9-15; DOI:10.1158/1535-7163.MCT-10-0677

Therapeutic Discovery

Therapeutic Discovery

Glutathione-Conjugate Transport by RLIP76 Is Required for Clathrin-Dependent Endocytosis and Chemical Carcinogenesis

Sharad S. Singhal, Dilki Wickramarachchi, Sushma Yadav, Jyotsana Singhal, Kathryn Leake, Rit Vatsyayan, Pankaj Chaudhary, Poorna Lelsani, Sumihiro Suzuki, Shaohua Yang, Yogesh C. Awasthi and Sanjay Awasthi

Mol Cancer Ther January 1 2011 10 (1) 16-28; DOI:10.1158/1535-7163.MCT-10-0699
Therapeutic Discovery

Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth

Huajun Zhao, Yuan-Hung Lo, Li Ma, Susan E. Waltz, Jerilyn K. Gray, Mien-Chie Hung and Shao-Chun Wang

Mol Cancer Ther January 1 2011 10 (1) 29-36; DOI:10.1158/1535-7163.MCT-10-0778
Therapeutic Discovery

Cell-Penetrating TAT-FOXO3 Fusion Proteins Induce Apoptotic Cell Death in Leukemic Cells

Makram Essafi, Alice D. Baudot, Xavier Mouska, Jill-Patrice Cassuto, Michel Ticchioni and Marcel Deckert

Mol Cancer Ther January 1 2011 10 (1) 37-46; DOI:10.1158/1535-7163.MCT-10-0482
Therapeutic Discovery

Prediction of Colorectal Cancer Relapse and Prognosis by Tissue mRNA Levels of NDRG2

Dake Chu, Zixi Zhang, Yunming Li, Lin Wu, Jing Zhang, Weizhong Wang and Jian Zhang

Mol Cancer Ther January 1 2011 10 (1) 47-56; DOI:10.1158/1535-7163.MCT-10-0614
Therapeutic Discovery

Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts

Carly Griffin, Aditya Karnik, James McNulty and Siyaram Pandey

Mol Cancer Ther January 1 2011 10 (1) 57-68; DOI:10.1158/1535-7163.MCT-10-0735
Therapeutic Discovery

A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis

Hongbo Wang, Xujun Ma, Shumei Ren, John K. Buolamwini and Chunhong Yan

Mol Cancer Ther January 1 2011 10 (1) 69-79; DOI:10.1158/1535-7163.MCT-10-0581
Therapeutic Discovery

Therapeutic Targeting the Loss of the Birt-Hogg-Dubé Suppressor Gene

Xiaohong Lu, Wenbin Wei, Janine Fenton, Michael S. Nahorski, Erzsebet Rabai, Anne Reiman, Laurence Seabra, Zsuzsanna Nagy, Farida Latif and Eamonn R. Maher

Mol Cancer Ther January 1 2011 10 (1) 80-89; DOI:10.1158/1535-7163.MCT-10-0628

Preclinical Development

Preclinical Development

A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma

Sofía Torres, Mar Lorente, Fátima Rodríguez-Fornés, Sonia Hernández-Tiedra, María Salazar, Elena García-Taboada, Juan Barcia, Manuel Guzmán and Guillermo Velasco

Mol Cancer Ther January 1 2011 10 (1) 90-103; DOI:10.1158/1535-7163.MCT-10-0688
Preclinical Development

Chemopreventive and Chemotherapeutic Effects of Intravesical Silibinin against Bladder Cancer by Acting on Mitochondria

Jin Zeng, Yi Sun, Kaijie Wu, Lei Li, Gang Zhang, Zenglei Yang, Zhiqiang Wang, Dong Zhang, Yan Xue, Yule Chen, Guodong Zhu, Xinyang Wang and Dalin He

Mol Cancer Ther January 1 2011 10 (1) 104-116; DOI:10.1158/1535-7163.MCT-10-0577
Preclinical Development

Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Xiaonan Hou, Fei Huang, Joan M. Carboni, Karen Flatten, Yan W. Asmann, Cynthia Ten Eyck, Takeo Nakanishi, Jennifer D. Tibodeau, Douglas D. Ross, Marco M. Gottardis, Charles Erlichman, Scott H. Kaufmann and Paul Haluska

Mol Cancer Ther January 1 2011 10 (1) 117-125; DOI:10.1158/1535-7163.MCT-10-0438
Preclinical Development

ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action

Graham C. Fletcher, Richard D. Brokx, Trisha A. Denny, Todd A. Hembrough, Stacy M. Plum, William E. Fogler, Carolyn F. Sidor and Mark R. Bray

Mol Cancer Ther January 1 2011 10 (1) 126-137; DOI:10.1158/1535-7163.MCT-10-0574
Preclinical Development

Celecoxib Can Induce Vascular Endothelial Growth Factor Expression and Tumor Angiogenesis

Kaiming Xu, Huiying Gao and Hui-Kuo G. Shu

Mol Cancer Ther January 1 2011 10 (1) 138-147; DOI:10.1158/1535-7163.MCT-10-0415
Preclinical Development

Luteinizing Hormone-Releasing Hormone (LHRH)-I Antagonist Cetrorelix Inhibits Myeloma Cell Growth In vitro and In vivo

Jianguo Wen, Yongdong Feng, Chad C. Bjorklund, Michael Wang, Robert Z. Orlowski, Zheng-Zheng Shi, Bing Liao, Jacqueline O'Hare, Youli Zu, Andrew V. Schally and Chung-Che Chang

Mol Cancer Ther January 1 2011 10 (1) 148-158; DOI:10.1158/1535-7163.MCT-10-0829
Preclinical Development

MEK/ERK Inhibitor U0126 Increases the Radiosensitivity of Rhabdomyosarcoma Cells In vitro and In vivo by Downregulating Growth and DNA Repair Signals

Francesco Marampon, Giovanni Luca Gravina, Agnese Di Rocco, Pierluigi Bonfili, Mario Di Staso, Caterina Fardella, Lorella Polidoro, Carmela Ciccarelli, Claudio Festuccia, Vladimir M. Popov, Richard G. Pestell, Vincenzo Tombolini and Bianca Maria Zani

Mol Cancer Ther January 1 2011 10 (1) 159-168; DOI:10.1158/1535-7163.MCT-10-0631
Preclinical Development

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

Tomoyuki Nagai, Tokuzo Arao, Kazuyuki Furuta, Kazuko Sakai, Kanae Kudo, Hiroyasu Kaneda, Daisuke Tamura, Keiichi Aomatsu, Hideharu Kimura, Yoshihiko Fujita, Kazuko Matsumoto, Nagahiro Saijo, Masatoshi Kudo and Kazuto Nishio

Mol Cancer Ther January 1 2011 10 (1) 169-177; DOI:10.1158/1535-7163.MCT-10-0544
Preclinical Development

Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101

Stephane Dalle, Lina Reslan, Timothee Besseyre de Horts, Stephanie Herveau, Frank Herting, Adriana Plesa, Thomas Friess, Pablo Umana, Christian Klein and Charles Dumontet

Mol Cancer Ther January 1 2011 10 (1) 178-185; DOI:10.1158/1535-7163.MCT-10-0385
Preclinical Development

Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo

Peter Jantscheff, Martin Schlesinger, Juliane Fritzsche, Lenka A. Taylor, Ralph Graeser, Gregor Kirfel, Dieter O. Fürst, Ulrich Massing and Gerd Bendas

Mol Cancer Ther January 1 2011 10 (1) 186-197; DOI:10.1158/1535-7163.MCT-10-0474
Preclinical Development

Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway

Esther P. Jane, Daniel R. Premkumar and Ian F. Pollack

Mol Cancer Ther January 1 2011 10 (1) 198-208; DOI:10.1158/1535-7163.MCT-10-0725

Molecular Medicine in Practice

Molecular Medicine in Practice

Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients with Advanced Malignancies: A Phase I Clinical Trial

Apostolia-Maria Tsimberidou, Chris H.M. Takimoto, Stacy Moulder, Cynthia Uehara, Monica Mita, Alain Mita, Patrick Urban, Eugene Tan, Yanfeng Wang, David Vining and Razelle Kurzrock

Mol Cancer Ther January 1 2011 10 (1) 209-217; DOI:10.1158/1535-7163.MCT-10-0774

Main menu

User menu

Search

Table of Contents

Highlights

Spotlight on Clinical Response

Review

Therapeutic Discovery

Preclinical Development

Molecular Medicine in Practice

Issue Highlights

Jump to

Articles

Info for

About MCT